Hybrid APC for Gastric Low Grade Intraepithelial Neoplasia
Launched by CHINESE UNIVERSITY OF HONG KONG · Dec 11, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called Hybrid APC for patients with a specific condition known as gastric low grade intraepithelial neoplasia (LGIN), which is a type of abnormal growth in the stomach lining. The goal is to find out how effective and safe this treatment is for patients with small areas of LGIN that are 20 millimeters or less in size. If you or a family member has been diagnosed with this condition through an endoscopy and biopsy, and you meet certain criteria, you might be eligible to participate in this study.
Eligible participants are typically adults aged 65 to 74 who have been confirmed to have gastric LGIN and have not had previous treatments for this condition. They should also be able to provide informed consent, which means they understand the study and agree to take part. If enrolled, participants can expect to receive the Hybrid APC treatment and be monitored for its effectiveness and any side effects. It's important to note that individuals with more severe conditions or certain health issues, like pregnancy or previous treatments, won't be able to join the trial. This study is currently recruiting participants, so it's a good opportunity for those who qualify to potentially benefit from this new treatment approach.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Low grade intraepithelial neoplasia of stomach with size≤20 mm
- • 2. Endoscopic diagnosis suspected gastric LGIN with biopsy confirmed gastric LGIN
- • 3. Endoscopic appearance according to Paris classification of Type 0-IIa, IIb or IIc
- • 4. Patients with informed consent
- Exclusion Criteria:
- • 1. Patients who had previous endoscopic treatment (including APC, EMR, ESD) for gastric LGIN, HGIN or gastric carcinoma.
- • 2. Endoscopic evidence of ulcer
- • 3. Biopsy confirmed HGIN
- • 4. Endoscopic diagnosis suspected HGIN while biopsy confirmed LGIN
- • 5. Pregnancy
- • 6. informed consent not available
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Philip WY Chiu, MD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials